Test Type: TOX

Route: Dosing in Water

Species/Strain: Mouse/B6C3F1/N

Study Number:

Study Gender:

PWG Approval Date

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sodium Metavanadate

CAS Number: 13718-26-8

194043

Female

See web page for date of PWG Approval

Date Report Requested: 09/02/2020 Time Report Requested: 10:28:30 Lab: Burleson Research Technologies

Test Type: TOX **Route:** Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sodium Metavanadate
CAS Number: 13718-26-8

Date Report Requested: 09/02/2020 Time Report Requested: 10:28:30 Lab: Burleson Research Technologies

Female: Immunopath

	Treatment Groups (ppm)						
	0	31.3	62.5	125	250	500	
Disposition Summary							
Animals Initially In Study	8	8	8	8	8	8	
Scheduled Sacrifice							
Early Deaths							
Survivors							
Scheduled sacrifice, terminal (SD 28)	8	8	8	8	8	8	
Animals Examined Microscopically	8	8	8	8	8	8	
ALIMENTARY SYSTEM							
LIVER	(8)	(8)	(8)	(8)	(8)	(8)	
CARDIOVASCULAR SYSTEM							
No Tissues/Organs Examined							
ENDOCRINE SYSTEM							
ADRENAL GLAND, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)	
GENERAL BODY SYSTEM							
No Tissues/Organs Examined							
GENITAL SYSTEM							
COAGULATING GLAND	(1)	(0)	(0)	(0)	(0)	(0)	
HEMATOLYMPHOID SYSTEM							
BALT	(8)	(8)	(8)	(8)	(8)	(8)	
BONE MARROW	(8)	(8)	(8)	(8)	(8)	(8)	
LYMPH NODE, MESENTERIC	(8)	(8)	(8)	(8)	(8)	(8)	
LYMPH NODE, POPLITEAL	(8)	(8)	(8)	(8)	(8)	(8)	
SPLEEN	(8)	(8)	(8)	(8)	(8)	(8)	
THYMUS	(8)	(8)	(8)	(8)	(8)	(8)	

Test Type: TOX **Route:** Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sodium Metavanadate
CAS Number: 13718-26-8

Date Report Requested: 09/02/2020 Time Report Requested: 10:28:30 Lab: Burleson Research Technologies

Fema	le:	Imm	uno	nath
ı cına			uiiv	patii

remale: Immunopath							
Treatment Groups (ppm)							
0	31.3	62.5	125	250	500		
(8)	(8)	(8)	(8)	(8)	(8)		
(1)	(0)	(0)	(0)	(0)	(0)		
(8)	(8)	(8)	(8)	(8)	(8)		
	(8)	(8) (8)	(8) (8) (8) (9) (1) (0) (0)	Treatment Groups (ppm) 0 31.3 62.5 125 (8) (8) (8) (8)	Treatment Groups (ppm) 0 31.3 62.5 125 250 (8) (8) (8) (8) (8) (8)		

Test Type: TOX **Route:** Dosing in Water

Primary Site

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sodium Metavanadate
CAS Number: 13718-26-8

Date Report Requested: 09/02/2020 Time Report Requested: 10:28:30 Lab: Burleson Research Technologies

Tumor Summary Data for Female Immunopath	Treatment Groups (ppm)						
	0	31.3	62.5	125	250	500	
Total Animals with Primary Neoplasms	0	0	0	0	0	0	
Total Primary Neoplasms	0	0	0	0	0	0	
Total Animals with Benign Neoplasms	0	0	0	0	0	0	
Total Benign Neoplasms	0	0	0	0	0	0	
Total Animals with Malignant Neoplasms	0	0	0	0	0	0	
Total Malignant Neoplasms	0	0	0	0	0	0	
Total Animals with Metastatic Neoplasms	0	0	0	0	0	0	
Total Metastatic Neoplasms	0	0	0	0	0	0	
Total Animals with Malignant Neoplasms Uncertain	0	0	0	0	0	0	

Test Type: TOX **Route:** Dosing in Water

Species/Strain: Mouse/B6C3F1/N

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Sodium Metavanadate **CAS Number:** 13718-26-8

Date Report Requested: 09/02/2020 Time Report Requested: 10:28:30 Lab: Burleson Research Technologies

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD - Study Day

** END OF REPORT **